JBF Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

JBF Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,000	Closed	-$382K	–	129
2018 Q3	$382K	Hold	5,000	–	–	0.06%	51
2018 Q2	$384K	Buy	+5,000	New	+$323K	0.06%	58

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JBF Capital's RARE Position: Q4 2018 in Review

JBF Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 5,000 shares — an estimated $382K sold.

JBF Capital first reported a position in RARE in Q2 2018 and held it in 2 quarters. The position peaked at $384K in Q2 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

JBF Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
JBF Capital sold 5,000 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $382K.
JBF Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 2 quarters.
JBF Capital's Ultragenyx Pharmaceutical position peaked at $384K in Q2 2018.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.